Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 28 · below the Ichimoku cloud · RSI 48 · MACD above its signal
| 5.33 | 52-week high | +783.04% |
| 0.7500 | Previous month high | +24.25% |
| 0.7176 | R3 (classic) | +18.88% |
| 0.6837 | R2 (classic) | +13.28% |
| 0.6499 | Previous day high | +7.67% |
| 0.6437 | R1 (classic) | +6.64% |
| 0.6100 | Previous week high | +1.06% |
| 0.6098 | Pivot | +1.03% |
| 0.6036 | Price now | |
| 0.5760 | Previous day low | −4.57% |
| 0.5698 | S1 (classic) | −5.61% |
| 0.5600 | Previous week low | −7.22% |
| 0.5359 | S2 (classic) | −11.21% |
| 0.5190 | Previous month low | −14.02% |
| 0.4959 | S3 (classic) | −17.85% |
| 0.4000 | 52-week low | −33.73% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $133.5K | 0.00% | 325.08K | +6.7% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MDXH trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.0 | -2.9 | -32.4 | -11.3 | -62.7 | -45.9 | 1.7 | 72.2 | -18.8 | 3.2 | −83.1% | ||
| 2025 | -19.4 | -4.7 | -22.0 | 21.8 | 21.7 | 5.0 | 8.1 | 48.5 | 31.0 | 5.8 | -25.0 | -3.3 | +50.6% |
| 2024 | 4.1 | -11.0 | -29.0 | -3.5 | 10.0 | -13.1 | 18.4 | 3.0 | -28.6 | -2.4 | -1.5 | 18.5 | −39.8% |
| 2023 | 0.9 | -41.4 | -17.1 | 11.4 | 0.8 | -6.3 | 7.9 | -18.5 | -6.7 | -2.5 | 18.3 | 22.0 | −40.4% |
| 2022 | -11.1 | 2.2 | -4.0 | -3.3 | -4.7 | 9.2 | -17.4 | 15.5 | -15.3 | 13.5 | -1.8 | -12.1 | −30.6% |
| 2021 | 4.8 | +4.8% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 12, 2026 | Mvm Partners LlpDirector | Purchase at price 0.45 per share. | 2.20M | $1.00M |
Buy / hold / sell counts
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.